IGF2BP2 and acute myeloid leukemia: One study showed that superenhancer‐driven H3K27ac, H3K4me1, and BRD4 significantly upregulate IGF2BP2 and IGF2BP3 in AML, stabilizing DDX21 mRNA in an m6A‐dependent manner.